1. Home
  2. |Insights
  3. |OCIs Down Air Force Award

OCIs Down Air Force Award

Client Alert | less than 1 min read | 09.14.09

In L-3 Servs., Inc. (Sept. 3, 2009) the GAO found unreasonable the Air Force's conclusions that the awardee did not have either a "biased ground rules" or "unequal access to information" OCI when the awardee's subcontractor had performed procurement planning services that put it in a position to affect the subsequent competition and that gave the subcontract access to non-public information that potentially conferred an unfair competitive advantage in that subsequent competition. The Air Force had initially gotten it right, determining that the subcontractor was barred from participating in the subsequent procurement, only to reverse that decision, thereby setting the stage for GAO's decision sustaining the protest.

Contacts

Insights

Client Alert | 7 min read | 09.14.26

AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development

Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage. ...

View All Insights